The Maybach Financial Group www.maybachfinancial.com will be researching the above-mentioned companies for our members. Visit www.maybachfinancial.com for a complimentary subscription to the Maybach service and receive at no cost our "Special Report#1: Protecting Our Future" plus a second free report "Special Report #2: Hearing is Believing" No credit card or payment information is required.
Today's activity has brought Abbott Laboratories on our radar.
Early trading, Friday February 22, 2008, Abbott Laboratories was down $0.77 with a trading volume nearing 2,000,000.
Friday February 22, 2008, Abbott announced it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older. In the U.S., JIA is commonly referred to as juvenile rheumatoid arthritis (JRA). The approval is based on safety and efficacy results from a clinical study of JIA patients four to 17 years of age. HUMIRA is the first biologic treatment to receive FDA approval for this condition since 1999, and the first to be administered by injection in these patients once every two weeks.
We've seen oil markets spike, we've seen oil markets fall. We've seen wars, we've seen terrorist attacks. Chances are that the events that occur have a short term impact when you consider the overall factors of a 5-year forecast.
Most investors -- and unfortunately far too many brokers -- go on a buying spree the minute a rally starts in a particular sector. Correspondingly, they panic at the first sign of a downturn and tend to sell off some great stocks - right before the dead cat bounces.
But Maybach isn't about day-trading and making money fast. It's about being patient and learning the secret of how to get rich slowly. Sign up now to receive Special Report #1: The Pick of the Decade"
It's also about adding stocks to your portfolio that have little or no effect against the state of the economy.
For a limited time only, gain access to Maybach and our reports free of charge with no credit card or payment information required. Visit www.maybachfinancial.com for your free subscription.
Maybach Financial (Maybach) is not a registered broker dealer or a registered investment advisor. No information accessed through the Maybach Web site or this release constitutes a recommendation to buy, sell or hold any security in any jurisdiction. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Please view the disclaimer at http://www.maybachfinancial.com/terms.php Statements made in this release may include forward-looking statements and projections, made in reliance on the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Maybach has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release. Maybach makes these statements and projections in good faith, neither Maybach nor its management can guarantee that the transactions will be consummated or that anticipated future results will be achieved. All material herein was based upon information believed to be reliable. The information contained herein is not guaranteed by Maybach to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Maybach assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by Maybach, whether as a result of new information, future events, or otherwise.
CONTACT: Maybach Financial e-mail: info@maybachfinancial.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
|
|
